Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
K.N. Chi(BC Cancer Agency), Eleni Efstathiou(The University of Texas MD Anderson Cancer Center), Karen Urtishak(Janssen (Switzerland)), Eric J. Small(CancerCare Manitoba), Gary Mason, Shiva Dibaj(Janssen (Switzerland)), A. del Corral(Janssen (United States)), Andrea Juliana Gomes, Peter Francis(Janssen (United States)), Daphne Wu(Janssen (United States)), Howard Gurney(Radboud University Nijmegen), Gerhardt Attard(Royal Marsden NHS Foundation Trust), Guilhem Roubaud(Institut Bergonié), David Olmos(Queen's University Belfast), B. Diorio(Janssen (United States)), Elena Castro(Hospital Universitario 12 De Octubre), Wonho Jung(Keimyung University), W. Kim(Janssen (Belgium)), Matthew R. Smith(Harvard University), Marniza Saad(University of Malaya), Shahneen Sandhu(Peter MacCallum Cancer Centre), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center)
Cited by 195
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k